New pill could tame tough psoriasis – early trial underway

NCT ID NCT07129382

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tests an experimental capsule called CS32582 in adults with moderate-to-severe plaque psoriasis. The trial has two parts: a short 4-week dose-finding phase and a longer 12-week phase to see how well the drug clears skin and whether it is safe. About 220 participants will take either the drug or a placebo.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
CS32582 capsule
What this could lead to
If successful, this could lead to a new oral treatment option for moderate-to-severe plaque psoriasis, helping to clear skin and reduce symptoms.
What could go wrong
This is an early phase 1/2 trial with a small number of participants, so safety and effectiveness are not yet proven. The drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PLAQUE PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Affiliated Hangzhou First People's Hospital, School of Medicine, Westlake University

    NOT_YET_RECRUITING

    Hangzhou, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Affiliated Hospital of Chengde Medical University

    NOT_YET_RECRUITING

    Chengde, Hebei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Beijing Friendship Hospital, Capital Medical University

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • First Hospital of Shanxi Medical University

    NOT_YET_RECRUITING

    Taiyuan, Shanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Peking University People's Hospital

    NOT_YET_RECRUITING

    Beijing, Beijing Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shandong Provincial Hospital for Skin Diseases

    NOT_YET_RECRUITING

    Jinan, Shandong, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Shiyan People's Hospital

    NOT_YET_RECRUITING

    Shiyan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Affliated Hospital of Wenzhou Medical University

    NOT_YET_RECRUITING

    Wenzhou, Zhengjiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The First Hospital of Hebei Medical University

    RECRUITING

    Shijiazhuang, Hebei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Fourth Affiliated Hospital of Zhejiang University School of Medicine

    NOT_YET_RECRUITING

    Yiwu, Zhejiang, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second Affiliated Hospital of Xi'an Jiaotong University(Xibei Hospital )

    NOT_YET_RECRUITING

    Xi’an, Shanxi, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.